On November 1, 2017 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) reported that it will present a corporate update at the Credit Suisse 26th Annual Healthcare Conference on Wednesday, November 8th, 2017 at 10:25 a.m. Mountain Time/ 12:25 p.m. Eastern Time at The Phoenician in Scottsdale, Arizona (Press release, Ironwood Pharmaceuticals, NOV 1, 2017, View Source [SID1234521434]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of Ironwood’s presentation will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. To access the webcast, please log on to the Ironwood website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Ironwood’s website for 14 days following the conference.

On November 1, 2017 Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, reported that Jacob Chacko, M.D., its Chief Financial Officer, will make a presentation at the Credit Suisse 26th Annual Healthcare Conference on Wednesday, November 8, 2017, at 11:35 a.m. Mountain time (10:35 a.m. Pacific time) in Scottsdale, AZ (Press release, Ignyta, NOV 1, 2017, View Source [SID1234521432]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the presentation will be available during the presentation in the Investors section of the company’s website at View Source, and will be archived and available at that site for 14 days.

On November 1, 2017 Diplomat Pharmacy, Inc. (NYSE: DPLO) reported that it has been named to the limited pharmacy panel to dispense CALQUENCE (acalabrutinib) (Press release, Diplomat Speciality Pharmacy, NOV 1, 2017, View Source [SID1234521424]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CALQUENCE, recently granted accelerated approval by the Food and Drug Administration, is indicated to treat mantle cell lymphoma (MCL)—a type of non-Hodgkin lymphoma—in adult patients who have received at least one prior therapy.

The average age at MCL diagnosis is the mid-60s, according to the Leukemia & Lymphoma Society.

“CALQUENCE is a needed alternative to treat a life-threatening blood cancer for patients who might not be responding to therapy or whose cancer has relapsed,” said Joel Saban, Diplomat president.

To learn more about Diplomat’s oncology program, visit diplomat.is/oncology.

CALQUENCE was developed by Acerta Pharma, LLC, a member of the AstraZeneca Group. For full prescribing information, click here.

On November 1, 2017 Servier, Pfizer Inc. (NYSE: PFE) and Cellectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS – Nasdaq: CLLS), reported that preliminary results from two phase 1 trials with UCART19, the allogeneic anti-CD19 CAR T-cell product being developed by Servier and Pfizer, will be presented during the 59th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition to be held in Atlanta on December 9-12 (Press release, Cellectis, NOV 1, 2017, View Source [SID1234521420]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Results from the CALM (UCART19 in Advanced Lymphoid Malignancies) study will be shared as an oral presentation by Reuben Benjamin, principal investigator and consultant hematologist at King’s College Hospital, United Kingdom, on December 11 at 7.15 pm (EST). The CALM study is an open label, dose-escalation study designed to evaluate safety, tolerability and antileukemic activity of UCART19 in patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (B-ALL). The study was initiated in the UK in August 2016.

The abstract for this presentation is available on the ASH (Free ASH Whitepaper) website: View Source

The PALL (Pediatric Acute Lymphoblastic Leukemia) study is a phase 1, open label, study to evaluate the safety and the ability of UCART19 to induce molecular remission in pediatric patients with relapsed or refractory B-ALL. PALL was initiated in the UK in June 2016. Waseem Qasim, principal investigator of the PALL study and consultant in pediatric immunology and reader in cell and gene therapy at Great Ormond Street Hospital for Children, United Kingdom, will present results from the trial during a poster session on December 9 from 5.30 pm to 7.30 pm.

The abstract for this presentation is available on the ASH (Free ASH Whitepaper) website: View Source

Servier is a sponsor of both studies. In 2015, Servier acquired exclusive rights from Cellectis for UCART19, which is being codeveloped by Servier and Pfizer.

About UCART19

UCART19 is an allogeneic CAR T-cell product candidate being developed for treatment of CD19-expressing hematological malignancies, gene edited with TALEN. UCART19 is initially being developed in acute lymphoblastic leukemia (ALL) and is currently in Phase I. The current approach with UCART19 is based on the preliminary positive results from clinical trials using autologous products based on the CAR technology. UCART19 has the potential to overcome the limitation of the current autologous approach by providing an allogeneic, frozen, “off-the-shelf” T cell based medicinal product.

In November 2015, Servier acquired the exclusive rights to UCART19 from Cellectis. Following further agreements, Servier and Pfizer began collaborating on a joint clinical development program for this cancer immunotherapy. Pfizer has been granted exclusive rights by Servier to develop and commercialize UCART19 in the United States, while Servier retains exclusive rights for all other countries.

On November 1, 2017 Cellectis (Alternext: ALCLS – Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), reported that abstracts regarding the Company’s allogeneic, off-the-shelf, CAR T product candidates have been accepted for presentation at the 59th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition (Press release, Cellectis, NOV 1, 2017, View Source [SID1234521419]). The meeting will be held from December 9 to 12, 2017 in Atlanta, GA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oral presentations:

UCARTCS1 product candidate targeting Multiple Myeloma
502. Universal SLAMF7-Specific CAR T-Cells As Treatment for Multiple Myeloma

Abstract: View Source

Session Name: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Novel Immunotherapeutic Strategies in Multiple Myeloma Session

Sunday, December 10, 2017 at 5:15 PM

Location: Bldg B, Lvl 3, B308-B309 (Georgia World Congress Center)

Rohit Mathur1, Zheng Zhang1, Jin He1, Roman Galetto2, Agnès Gouble2, Isabelle Chion-Sotinel2, Stéphanie Filipe2, Annabelle Gariboldi2, Tanooha Veeramachaneni1, Elisabet E. Manasanch1, Sheeba K. Thomas1, Hans C. Lee1, Krina K. Patel1, Donna M. Weber1, R. Eric Davis1, Robert Z. Orlowski1, Julianne Smith3, Jing Yang1, and Sattva S. Neelapu1

1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA

2Cellectis SA, 8 rue de la croix Jarry, 75013 Paris, France

3Cellectis Inc, 430 East 29th Street, 10016 New York, NY, USA



UCART22 product candidate targeting B-Acute Lymphoblastic Leukemia
808. Pre-clinical Activity of Allogeneic Anti-CD22 CAR T-Cells for the Treatment of B-cell Acute Lymphoblastic Leukemia

Abstract: View Source

Session Name: 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: CAR-T Cell Immunotherapy

Monday, December 11, 2017: 5:15 PM

Location: Bldg C, Lvl 1, Hall C4 (Georgia World Congress Center)



Julia Wells PhD1, Tianyu Cai, PhD1, Cécile Schiffer-Manniou PhD2, Stéphanie Filipe, PhD2, Agnès Gouble, PhD2, Roman Galetto, PhD2, Nitin Jain MD1, Elias Jabbour MD1, Julianne SmithPhD3 and Marina Konopleva, MD, PhD1

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

2Cellectis SA, Paris, France

3Cellectis Inc, New York, NY

Poster Presentation:

UCART123 product candidate targeting Blastic Plasmacytoid Dendritic Cell Neoplasm
2625. Pre-Clinical Studies of Allogeneic Anti-CD123 CAR T-Cells for the Therapy of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Abstract: View Source

Session Name: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II

Sunday, December 10, 2017 from 6:00 PM to 8:00 PM

Location: Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center)

Tianyu Cai1, Roman Galetto2, Agnès Gouble2, Julianne Smith3, Antonio Cavazos1, Lina Han1, Qi Zhang1, Vinitha Kuruvilla1, Sergej Konoplev4, Sattva S. Neelapu5, Andrew A. Lane6, Monica Guzman7, Hagop Kantarjian1, Naveen Pemmaraju1, Marina Konopleva1

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

2Cellectis SA, Paris, France

3Cellectis Inc, New York, NY

4Department of Hematopathology, The University of MD Anderson Cancer Center, Houston, TX

5Department of Lymphoma and Myeloma, The University of MD Anderson Cancer Center, Houston, TX

6Dana-Farber Cancer Institute, Boston

7Department of Medicine, Weill Cornell Medical College, New York, NY